London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I have noticed the share dips for the US opening bell... they do love a bargain!
I think there will be a temporary dip coming up soon (profit takers) but long term it will keep rising. The great thing now is that even if the end of year figures still show Generics under pressure the reaction will not be as bad because major steps are now being taken to address the matter. It's important to note that Hikma also appointment a new Chief Scientist who has a great reputation but that was largely ignored by the market but could prove to be equally relevant to driving the business forward.
Thee has been a lot of trading with this share, not just shorters....it fell to a ridiculously low price during the Dow Jones fall back....today, in many ways is just getting it back to the minimum ...1100p is a value for the company, even without the generics ...is what i read
Poachers turning into gamekeepers Jimbo! They are probably scrambling all their trolls into action stations to push the price down.
Now up 140p (15%). The shorters must be going mental now.
In out, in out, you shake it all about!!
Good news is in the price. Will open a new position after results.
Let's also see if the new CEO makes significant share purchases in the near future. That, and positive news on Advair, and the shares will rocket.
An excellent appointment...his experience with the generics big-boy Teva will be very useful....he is clearly going to help form future strategy,aquisitions, and company direction....very interesting
Fantom--i have reported you to the moderator. Singing is not allowed on this forum (LOL).
Reasons to be Cheerful () Reasons to be Cheerful () Reasons to be Cheerful () Reasons to be Cheerful - one, two, three!
Definitely achieveable Fantom. As Ian Dury would say we have "Reasons to be cheerful"
It wouldn't be unreasonable now to expect six months of appreciation to 1680 (double our recent low).
Seems he has promising deal for hikma...
Mr Olafsson has significant international experience in the pharmaceutical industry. He was most recently President and Chief Executive Officer of the Global Generic Medicines Group of Teva Pharmaceuticals, a position he held from 2014 to 2016. From 2012 to 2014, he was President of Actavis. Prior to this, he was Executive Vice President, Global Generics, at Actavis plc (Watson) from 2010 to 2012; and CEO of the Actavis Group from 2008 to 2010. From 2003 to 2008, he held positions of increasing responsibility within the Actavis Group, including Deputy CEO, Vice President of Corporate Development and CEO of Actavis Inc. US. From 1998 to 2003, he held positions of increasing responsibility with Pfizer's Global R&D organization in the UK and US. From 1994 to 1998, he served as Head of Drug Development for Omega Farma in Iceland. He currently serves as a member of the board of directors for Elucida Oncology and Pfenex Inc. Mr Olafsson received a M.S. in pharmacy (Cand Pharm) from the University of Iceland, Reykjavik. Mr Olafsson is an independent director of Pfenex Inc, a biologics company listed on the New York Stock Exchange. Mr Olafsson was a director of Actavis PLC, a pharmaceutical company previously listed on the NASDAQ, from October 2013 to May 2014. Otherwise, Mr Olafsson has not held any directorships in any other publicly listed companies during the previous five years. Mr Olafsson does not have any relationship with any directors, senior management, substantial or controlling shareholders of Hikma, and, as at the date of this announcement, does not own ordinary shares of Hikma.
Who is new CEO qualification? I mean experience..
I think this will be the announcement that drives out the shorters and hastens a turnaround in share decline
Can you imagine the wealth of knowledge and extensive contacts this new CEO will bring to Hikma. Not tempted to sell because this SP will only go one way now - - - UP.
ah, change CEO.....
@�150 pp. This to me is good news
I struggle to see how the coming announcement could push the SP any higher, does that make and sense to anyone else. What do the board need to do to turn this general fall around?
I struggle to see how the coming announcement could push the SP any higher, does that make and sense to anyone else. What do the board need to do to turn this general fall around?
Big bounce in the last 30mins (up 25p). Probably Deutsche Bank buying back the shares they keep selling - - i wish they would make up their minds.
Great news guys, just what we need. Buffet has been buying up a stake in TEVA. https://www.bloomberg.com/gadfly/articles/2018-02-14/teva-warren-buffett-messed-things-up-for-short-sellers Sign the generic squeeze is coming to an end?
I wouldn't read too much into the Vectura bounce (off the 0% monthly chart base line). That isn't an absolute bottom line, it could be forced lower.